The Alzheimer’s Drug Discovery Foundation will be moderating a session, “Beyond Amyloid and Tau: Emerging Solutions,” at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference, which will be held November 29th through December 2nd at the Hilton Union Square in San Francisco, California.
Related Posts
Senolytics in the News
- Fighting aging with immune checkpoint blockade
- Despite Their Scary Name, Some ‘Zombie’ Cells May Not Be All Bad
- Focus on frailty: New senolytic holds potential for sarcopenia treatment
- Progress in Emerging Alzheimer’s Therapeutics Based on Biology of Aging to be Highlighted in Session Moderated by Alzheimer’s Drug Discovery Foundation (ADDF) at 2022 Clinical Trials on Alzheimer’s Disease Conference
- Senolytic treatment shows promise in DME, wet AMD